The Oral Calcilytic Encaleret Decreased the Fractional Excretion of Calcium in Individuals with Post-surgical Hypoparathyroidism: Preliminary Findings from an Ongoing Open-label Phase 2 Study

被引：0
|
作者：
Gafni, Rachel I. [1 ]
Roszko, Kelly L. [1 ]
Li, Xiaobai [2 ]
Ferguson, Elizabeth A. [1 ]
Moore, Casey A. [1 ]
Pozo, Karen A. [1 ]
Ampuero, Kimberly T. [1 ]
Meadows, Rita E. J. [1 ]
Sridhar, Ananth V. [3 ]
Mathew, Arun S. [3 ]
Roberts, Mary Scott [3 ]
Adler, Scott H. [3 ]
Nemeth, Edward F. [4 ]
Collins, Michael T. [1 ]
机构：
[1] Nat Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA
[2] NIH, Biostat & Clin Epidemiol, Clin Ctr, Bethesda, MD USA
[3] Calcilytix Therapeut Inc, San Francisco, CA USA
[4] MetisMedica, Montreal, PQ, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-LB 591
引用
收藏
页码：360 / 361
页数：2
相关论文
共 50 条
  • [41] Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study
    Lim, Young-Suk
    Lin, Chun-yen
    Heo, Jeong
    Bae, Ho
    Chuang, Wan-Long
    Tsang, Tak Yin Owen
    Fournier, Claire
    Hui, Aric Josun
    Huy Trinh
    Tan, Susanna
    Zhao, Yang
    Flaherty, John F.
    Suri, Vithika
    Gaggar, Anuj
    Brainard, Diana
    Ryder, Stephen
    Janssen, Harry L. A.
    JOURNAL OF HEPATOLOGY, 2021, 75 : S755 - S756
  • [42] Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
    Stathis, Anastasios
    Maddocks, Kami J.
    Flinn, Ian
    Mejia, Alex
    Palomba, Maria Lia
    Zildjian, Sybil
    Murphy, Mary
    Deckert, Jutta
    Ruiz-Soto, Rodrigo
    Freedman, Arnold
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study
    Vidal, G.
    Kalinsky, K.
    Stringer-Reasor, E.
    Lynce, F.
    Cole, J.
    Valdes-Albini, F.
    Soliman, H.
    Nikolinakos, P.
    Silber, A.
    DeMichele, A.
    Ali, H.
    Graham, D.
    Giguere, J.
    Brufsky, A.
    Liang, Y.
    Holland, S.
    Fiji, G.
    O'Keeffe, B.
    Gogineni, K.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
    Witzig, Thomas E.
    Sokol, Lubomir
    Foss, Francine M.
    Kim, Won-Seog
    Jacobsen, Eric
    De La Cruz, Maria de Fatima
    Caballero, Dolores
    Advani, Ranjana H.
    Roncero, Jose Maria
    Ona, Raquel de
    Niebla, Ana Marin
    Izquierdo, Antonia Rodriguez
    Terol, Maria Jose
    Domingo-Domenech, Eva
    Piris, Miguel A.
    Rodriguez, Marta
    Bolognese, James
    Kessler, Linda
    Mishra, Vishnu
    Curry, Robert
    Kurman, Michael
    Scholz, Catherine
    Gualberto, Antonio
    BLOOD, 2019, 134
  • [45] PRELIMINARY ANTI-TUMOR ACTIVITY AND SAFETY RESULTS FROM ADVANCED-2: A PHASE 2 OPEN-LABEL STUDY OF INTRAVESICAL TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    Jayram, Gautam T.
    Kramolowsky, Eugene
    Doronina, Myroslava
    Tabayoyong, William
    Mazzarella, Brian
    Zummo, Jacqueline
    Sun, Wei
    Belani, Khushboo
    Brown, Eppie
    Difiglia, Andrea
    Middleton, Claire
    Desch, Brian
    Lam, Chen Quin
    Shore, Neal
    Lysak, Zoreslava
    Levenko, Evgeny
    JOURNAL OF UROLOGY, 2025, 213 (5S):
  • [46] Nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Preliminary results from an open-label, single-arm, phase 2 study
    Jiang, Zhichao
    Zhang, Wen
    Yang, Lin
    Sun, Yongkun
    Zhao, Yun-Bo
    Deng, Wei
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
    Janku, F.
    Abdul-Karim, R.
    Azad, A.
    Bendell, J.
    Gan, H.
    Sen, S.
    Tan, T.
    Wang, J.
    Marina, N.
    Baker, L.
    Ma, L.
    Mooney, J.
    Luo, D.
    Leveque, J.
    Milla, M.
    Meniawy, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S11 - S11
  • [48] Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study
    Inagaki, Nobuya
    Sano, Hiroki
    Seki, Yoshifumi
    Kuroda, Shingo
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 354 - 359
  • [49] XEN1101, a novel, potent potassium channel modulator: Interim data from an ongoing, long-term, open-label extension of a Phase 2b study (X-TOLE) in adults with focal onset seizures (FOS)
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M. A.
    Harden, C.
    Qian, J.
    Rosenblut, C. Luzon
    Kenney, C.
    Beatch, G. N.
    EPILEPSIA, 2024, 65 : 184 - 184
  • [50] An open-label, phase 1/2 study of miransertib (ARQ 092), an oral pan-AKT inhibitor, in patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS): study design and preliminary results(NCT03094832)
    Zampino, G.
    Leoni, C.
    Buonuomo, P. S.
    Rana, I.
    Onesimo, R.
    Macchiaiolo, M.
    Diociaiuti, A.
    Livadiotti, S.
    Resta, N.
    Sheldon, Y.
    Savage, R.
    Lamar, M.
    Tith, K.
    Kazakin, J.
    Schwartz, B.
    Adams, D. M.
    Bartuli, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1136 - 1136
12345